Provided by Tiger Fintech (Singapore) Pte. Ltd.

AbCellera Biologics

3.70
+0.00500.14%
Volume:1.32M
Turnover:4.83M
Market Cap:1.11B
PE:-6.41
High:3.72
Open:3.65
Low:3.54
Close:3.69
52wk High:6.52
52wk Low:1.89
Shares:299.34M
Float Shares:202.75M
Volume Ratio:0.71
T/O Rate:0.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5768
EPS(LYR):-0.5533
ROE:-16.81%
ROA:-10.43%
PB:1.15
PE(LYR):-6.68

Loading ...

Company Profile

Company Name:
AbCellera Biologics
Exchange:
NASDAQ
Establishment Date:
2012
Employees:
596
Office Location:
150 West 4th Ave,Vancouver,British Columbia,Canada
Zip Code:
V5Y 1G6
Fax:
- -
Introduction:
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Directors

Name
Position
Carl L. G. Hansen
Chief Executive Officer, President and Director
Michael Hayden
Lead Director
Véronique Lecault
Chief Technology Officer and Director
John S. Montalbano
Director
Stephen Quake
Director

Shareholders

Name
Position
Carl L. G. Hansen
Chief Executive Officer, President and Director
Andrew Booth
Chief Financial Officer
Tryn Stimart
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer
Véronique Lecault
Chief Technology Officer and Director